118 related articles for article (PubMed ID: 18277616)
1. Solvent effects on physicochemical behavior of estradiols recrystallized for transdermal delivery.
Park JS; Park YJ; Kang HW; Kim CK
Arch Pharm Res; 2008 Jan; 31(1):111-6. PubMed ID: 18277616
[TBL] [Abstract][Full Text] [Related]
2. Use of CP/MAS solid-state NMR for the characterization of solvate molecules within estradiol crystal forms.
Park JS; Kang HW; Park SJ; Kim CK
Eur J Pharm Biopharm; 2005 Aug; 60(3):407-12. PubMed ID: 15996582
[TBL] [Abstract][Full Text] [Related]
3. Physical characterization of oleanolic acid nonsolvate and solvates prepared by solvent recrystallization.
Tong HH; Wu HB; Zheng Y; Xi J; Chow AH; Chan CK
Int J Pharm; 2008 May; 355(1-2):195-202. PubMed ID: 18207676
[TBL] [Abstract][Full Text] [Related]
4. Crystal modification of phenytoin using different solvents and crystallization conditions.
Nokhodchi A; Bolourtchian N; Dinarvand R
Int J Pharm; 2003 Jan; 250(1):85-97. PubMed ID: 12480275
[TBL] [Abstract][Full Text] [Related]
5. Effect of crystal habit on the dissolution behaviour of simvastatin crystals and its relationship to crystallization solvent properties.
Bukovec P; Benkic P; Smrkolj M; Vrecer F
Pharmazie; 2016 May; 71(5):263-8. PubMed ID: 27348970
[TBL] [Abstract][Full Text] [Related]
6. Solvents effects on crystallinity and dissolution of β-artemether
Xu J; Singh V; Yin X; Singh P; Wu L; Xu X; Guo T; Sun L; Gui S; Zhang J
Drug Dev Ind Pharm; 2017 Mar; 43(3):372-378. PubMed ID: 27781497
[TBL] [Abstract][Full Text] [Related]
7. Solid-State Characterization and Interconversion of Recrystallized Amodiaquine Dihydrochloride in Aliphatic Monohydric Alcohols.
Sirikun W; Chatchawalsaisin J; Sutanthavibul N
AAPS PharmSciTech; 2016 Apr; 17(2):427-35. PubMed ID: 26206402
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the solubility and dissolution properties of several new rifampicin polymorphs, solvates, and hydrates.
Henwood SQ; Liebenberg W; Tiedt LR; Lötter AP; de Villiers MM
Drug Dev Ind Pharm; 2001 Nov; 27(10):1017-30. PubMed ID: 11794804
[TBL] [Abstract][Full Text] [Related]
9. Crystallization of beta-estradiol in an acrylic transdermal drug delivery system.
Variankaval NE; Jacob KI; Dinh SM
J Biomed Mater Res; 1999 Mar; 44(4):397-406. PubMed ID: 10397943
[TBL] [Abstract][Full Text] [Related]
10. Conformation transition of Bombyx mori silk protein monitored by time-dependent fourier transform infrared (FT-IR) spectroscopy: effect of organic solvent.
Chen X; Cai H; Ling S; Shao Z; Huang Y
Appl Spectrosc; 2012 Jun; 66(6):696-9. PubMed ID: 22732542
[TBL] [Abstract][Full Text] [Related]
11. Effects of solvents and crystallization conditions on the polymorphic behaviors and dissolution rates of valsartan.
Tran TT; Tran PH; Park JB; Lee BJ
Arch Pharm Res; 2012 Jul; 35(7):1223-30. PubMed ID: 22864745
[TBL] [Abstract][Full Text] [Related]
12. Recrystallization of fluconazole using the supercritical antisolvent (SAS) process.
Park HJ; Kim MS; Lee S; Kim JS; Woo JS; Park JS; Hwang SJ
Int J Pharm; 2007 Jan; 328(2):152-60. PubMed ID: 16959448
[TBL] [Abstract][Full Text] [Related]
13. Controlled release of beta-estradiol from PLAGA microparticles: the effect of organic phase solvent on encapsulation and release.
Birnbaum DT; Kosmala JD; Henthorn DB; Brannon-Peppas L
J Control Release; 2000 Apr; 65(3):375-87. PubMed ID: 10699296
[TBL] [Abstract][Full Text] [Related]
14. Influence of the solvent ability to form hydrogen bonds in the crystal structure of ([3beta,5beta,7alpha,12alpha]-3[(norbornyl-2-acetyl)-amino]-7,12-dihydroxycholan-24-oic acid (a norbornyl derivative of cholic acid).
Miragaya J; Jover A; Fraga F; Meijide F; Tato JV
Steroids; 2009 Sep; 74(9):735-41. PubMed ID: 19551911
[TBL] [Abstract][Full Text] [Related]
15. PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug.
Sahana DK; Mittal G; Bhardwaj V; Kumar MN
J Pharm Sci; 2008 Apr; 97(4):1530-42. PubMed ID: 17722098
[TBL] [Abstract][Full Text] [Related]
16. Preparation and physicochemical and preclinical evaluations of recrystallized celecoxib.
Mutalik S; Usha N; Ranjith AK; Umesh S; Musmade P; Anup N
PDA J Pharm Sci Technol; 2007; 61(5):362-74. PubMed ID: 18047175
[TBL] [Abstract][Full Text] [Related]
17. Solid-state characterization of tacrine hydrochloride.
Sorrenti M; Catenacci L; Bruni G; Luppi B; Bigucci F; Bettinetti G
J Pharm Biomed Anal; 2012 Apr; 63():53-61. PubMed ID: 22326286
[TBL] [Abstract][Full Text] [Related]
18. Assessment of response of the Intoxilyzer 8000C to volatiles of forensic relevance in vitro, part I: acetone, isopropanol, and methanol.
Watterson JH
J Anal Toxicol; 2009 Mar; 33(2):109-17. PubMed ID: 19239737
[TBL] [Abstract][Full Text] [Related]
19. beta-Estradiol biodegradable microspheres: effect of formulation parameters on encapsulation efficiency and in vitro release.
Zaghloul AA
Pharmazie; 2006 Sep; 61(9):775-9. PubMed ID: 17020154
[TBL] [Abstract][Full Text] [Related]
20. Can crystal engineering be as beneficial as micronisation and overcome its pitfalls?: A case study with cilostazol.
Sai Gouthami K; Kumar D; Thipparaboina R; Chavan RB; Shastri NR
Int J Pharm; 2015 Aug; 491(1-2):26-34. PubMed ID: 26068197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
